

Financial Results for FY2024

(April 1, 2024 - March 31, 2025)

&

Outlook for FY2025

(April 1, 2025 - March 31, 2026)

May 14, 2025



(Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

1. Consolidated Financial Results for FY2024 Ended March 31, 2025

Summary for FY2024 Financial Results	4
Financial Summary	5
Sales Revenue by Business Segment	6
Core Operating Income by Business Segment	7
Consolidated Statement of Financial Position	8
Consolidated Statement of Cash Flows	9

2. Outlook for FY2025 Ending March 31, 2026


Summary of the Financial Forecast for FY2025	11
FY2025 Outlook for the Business Environment	12
Regarding the Impact of the US's Tariff Policy	13
Financial Summary	14
Sales Revenue by Business Segment	15
Core Operating Income by Business Segment	16
Consolidated Statement of Cash Flows	17

(Reference)

Sales Revenue by Business Segment (Quarterly)	19
Core Operating Income by Business Segment (Quarterly)	20
Sales Revenue Analysis by Business Segment (FY2024)	21
Core Operating Income Analysis by Business Segment (FY2024)	24
Segment Analysis (FY2025 forecast)	29
Cost Elements etc.	34
Cost Elements etc. by Business Segment	35
Cost Elements etc. by Business Segment (Forecast) ..	36
Major Group Companies	37
Crop Protection Product Sales by Region	38
Overseas Sales Revenue	39
Sales Revenue and Profits	40
Interest-bearing Liabilities and D/E Ratio	41
Shareholder Returns	42

1. Consolidated Financial Results for FY2024 Ended March 31, 2025

Actual Results for FY2024



Core operating income was 140.5 billion yen

(up 289.6 billion yen from the prior year)

(up 40.5 billion yen from the forecast announced in February 2025)

- Core operating income for FY2024 improved by approximately 290.0 billion yen from the prior year, and we achieved a V-shaped recovery from a historic core operating loss.
- Compared to the prior forecast, there was a greater increase in revenue due to an increase in sales of the three key products in Sumitomo Pharma and sales of display materials in ICT & Mobility Solutions.
- For capital gains on business dispositions, although some of them were deferred to the next fiscal year, results were mostly as expected.
- In terms of underlying performance as well, we achieved steady improvement in each quarter.
- ROIC was 2.2%.


	(Billions of yen)			
	FY2024	FY2023	Variance	Variance Ratio
Sales revenue	2,606.3	2,446.9	159.4	6.5%
Core operating income (loss)	140.5	(149.0)	289.6	-
Of which equity in earnings	(62.9)	(52.6)	(10.4)	-
Total non-recurring items	52.5	(339.8)	392.3	-
Of which share of profit (loss) of investments accounted for using the equity method (non-recurring factors)	83.6	(4.8)	88.4	-
Of which gains on sales of property, plant and equipment, and intangible assets	14.3	1.2	13.1	-
Of which gains(losses) on fair value measurement of the residual interest	9.4	(2.5)	11.9	-
Of which impairment losses	(26.3)	(269.4)	243.1	-
Of which restructuring costs	(23.6)	(48.4)	24.8	-
Others	(4.9)	(15.9)	11.0	-
Operating income (loss)	193.0	(488.8)	681.9	-
Finance income/expenses	(134.9)	26.0	(161.0)	-
Of which gain (loss) on foreign currency transactions including gain (loss) on derivatives	(10.9)	32.5	(43.4)	-
Of which loss on debt waiver for a loan	(109.8)	-	(109.8)	-
Others	(14.2)	(6.4)	(7.8)	-
Income (loss) before taxes	58.1	(462.8)	520.9	-
Income tax expenses	(15.4)	(2.7)	(12.7)	-
Net income (loss)	42.7	(465.4)	508.1	-
Net (income) loss attributable to non-controlling interests	(4.1)	153.6	(157.7)	-
Net income (loss) attributable to owners of the parent	38.6	(311.8)	350.4	-
ROE	4.1%	(29.2%)		
Exchange rate (yen/\$)	152.62	144.59		
Naphtha price (yen/kl)	75,800	69,100		
Overseas sales revenue ratio	69.9%	68.0%		

Sales Revenue by Business Segment

(Billions of yen)

	FY2024	FY2023	Variance	Ratio	Sales price variance	Shipping volume variance	Foreign currency conversion variance
Agro & Life Solutions	540.2	515.6	24.6	4.8%	(7.0)	25.4	6.2
ICT & Mobility Solutions	607.0	587.4	19.6	3.3%	(3.5)	12.9	10.2
Advanced Medical Solutions	62.1	58.5	3.7	6.3%	0.0	3.5	0.2
Essential & Green Materials	899.0	885.9	13.2	1.5%	33.5	(44.0)	23.7
Sumitomo Pharma	398.0	313.8	84.2	26.8%	(5.0)	73.7	15.5
Others	99.9	85.8	14.1	16.5%	0.0	14.1	0.0
Total	2,606.3	2,446.9	159.4	6.5%	18.0	85.6	55.8

Analysis of Variance




Core Operating Income by Business Segment

7

(Billions of yen)

	FY2024	FY2023	Variance	Price variance	Cost variance	Shipping volume variance and other
Agro & Life Solutions	55.0	26.4	28.6	14.0	0.0	14.6
ICT & Mobility Solutions	70.6	50.0	20.5	(2.5)	3.5	19.5
Advanced Medical Solutions	4.0	6.1	(2.1)	0.0	(2.0)	(0.1)
Essential & Green Materials	(58.5)	(89.1)	30.6	23.5	3.5	3.6
Sumitomo Pharma	35.3	(126.4)	161.8	(5.0)	117.5	49.3
Others & Adjustments	34.2	(16.0)	50.2	0.0	0.0	50.2
Total	140.5	(149.0)	289.6	30.0	122.5	137.1

Analysis of Variance



Consolidated Statement of Financial Position

8

(Billions of yen)

	31-Mar-25	31-Mar-24	Variance		31-Mar-25	31-Mar-24	Variance
Current assets	1,583.1	1,675.9	(92.7)	Liabilities	2,365.4	2,770.5	(405.1)
Cash and cash equivalents	209.8	217.4	(7.6)	Trade and other payables	488.1	543.4	(55.3)
Trade and other receivables	593.8	620.0	(26.2)	Interest-bearing liabilities	1,286.1	1,563.5	(277.4)
Inventories	625.2	709.6	(84.4)	Others	591.1	663.6	(72.5)
Others	154.2	128.8	25.4	Equity	1,074.4	1,164.4	(90.0)
Non-current assets	1,856.7	2,258.9	(402.3)	Shareholders' equity	722.3	660.0	62.3
Property, plant and equipment	759.3	796.5	(37.3)	Other components of equity	178.5	305.8	(127.3)
Goodwill and intangible assets	497.1	536.7	(39.5)	Non-controlling interests	173.6	198.6	(25.0)
Others	600.3	925.7	(325.5)				
Total	3,439.8	3,934.8	(495.0)	Total	3,439.8	3,934.8	(495.0)
				Equity attributable to owners of parent to total	26.2%	24.5%	1.6%
				D/E ratio (times)	1.20	1.34	(0.15)

Consolidated Statement of Cash Flows


9

(Billions of yen)

	FY2024	FY2023	Variance
Cash flows from operating activities	233.0	(51.3)	284.3
Cash flows from investing activities	85.2	(112.2)	197.5
Free cash flows	318.3	(163.6)	481.8
Cash flows from financing activities	(300.8)	49.2	(350.0)
Others	(6.8)	28.7	(35.6)
Increase (decrease) in cash and cash equivalents	10.7	(85.6)	96.2
Cash and cash equivalents at end of period	209.8	217.4	(7.6)

2. Outlook for FY2025 Ending March 31, 2026

Forecast for FY2025



Core operating income is projected to be 150.0 billion yen (up 9.5 billion yen from the prior year)

Net income attributable to owners of the parent is projected to be 40.0 billion yen (up 1.4 billion yen from the prior year)

- Core operating income for FY2025 is projected to be **150.0 billion yen**.
- In terms of profit and loss in our underlying performance excluding the business dispositions, we project that, although there will be negative effects from currency fluctuations, there will also be a significant increase in profit from such factors as **an increase in shipments in each segment** and **a decrease in losses on investments accounted for using the equity method as a result of the decrease in ownership interest in Petro Rabigh**. We will aim for a profit of **100.0 billion yen**.
- For capital gains on business dispositions, we anticipate the disposition of **Sumitomo Pharma's business in Asia**, but project there will be a slight decline compared to the previous year.

Economic Conditions

- In the midst of increasing uncertainty over trade friction and policy management, the future prospects of the global economy will face an increased risk of a downturn. As financial market fluctuations and geopolitical risks continue, the path toward a stable recovery is difficult to foresee from such factors as uneven growth in regions.

Business Environment

FY24

FY25

Act.

Forecast

Forecast for FY25

Crop Protection



Inventories in the overseas distribution chain for crop protection chemicals will be reduced and price competition will continue.

Methionine



There will be a lull in the improvements in the methionine market, and it is expected to decline.

Displays



There will be steady growth in devices-related components.

Semiconductors



Demand for semiconductors will show signs of a gradual recovery.

Petrochemicals/ Raw Materials



The petrochemical market will continue to have low margins.

FY2024 sales in the US: approximately 400.0 billion yen (of this, two-thirds was in Sumitomo Pharma)

Direct impact

Increased tariff costs due to our facilities in the US procuring raw material from outside of the US

- The tariff policy on pharmaceutical products has not been decided at the present point in time. But we anticipate that, even if it were to be implemented, the impact would be minimal due to the small amount of transaction value subject to the tariff.
- Regarding other businesses, we anticipate that we will limit the impact of the tariff policy through such countermeasures as passing on the cost to consumers, shipments within the tariff grace period, and the optimization of our global production and sales system.

Indirect impact

Impact on the supply chain and macroeconomic impact from a global economic recession

- At the present point in time, uncertainty is high and we are unable to foresee the situation, so this is not incorporated into our financial forecast. We have, however, included only the impact of shipments frontloaded in FY2024 in a portion of our businesses.

(Billions of yen)

	FY2025 (Forecast)	FY2024	Variance	Variance ratio
Sales revenue	2,340.0	2,606.3	(266.3)	(10.2)%
Core operating income	150.0	140.5	9.5	6.7%
Non-recurring items	(45.0)	52.5	(97.5)	-
Operating income	105.0	193.0	(88.0)	(45.6)%
Net income attributable to owners of the parent	40.0	38.6	1.4	3.7%
ROE	4.2%	4.1%		
Exchange rate (yen/\$)	145.00	152.62		
Naphtha price (yen/kl)	68,000	75,800		
Cash dividends (yen)	Interim dividend	6.00	3.00	
	Year-end dividend	6.00	6.00	
	Annual dividend	12.00	9.00	


Sales Revenue by Business Segment

15

(Billions of yen)

	FY2025 (Forecast)	FY2024	Variance	Ratio	Sales price variance	Shipping volume variance	Foreign currency conversion variance
Agro & Life Solutions	530.0	540.2	(10.2)	(1.9)%	(3.0)	(4.3)	(2.9)
ICT & Mobility Solutions	580.0	607.0	(27.0)	(4.4)%	(8.0)	(22.8)	3.8
Advanced Medical Solutions	60.0	62.1	(2.1)	(3.5)%	-	(1.8)	(0.3)
Essential & Green Materials	780.0	899.0	(119.0)	(13.2)%	2.5	(106.7)	(14.8)
Sumitomo Pharma	350.0	398.0	(48.0)	(12.1)%	(4.0)	(34.9)	(9.1)
Others	40.0	99.9	(59.9)	(60.0)%	-	(59.9)	-
Total	2,340.0	2,606.3	(266.3)	(10.2)%	(12.5)	(230.3)	(23.4)

Analysis of Variance




Core Operating Income by Business Segment

16

(Billions of yen)

	FY2025 (Forecast)	FY2024	Variance	Price variance	Cost variance	Shipping volume variance and other
Agro & Life Solutions	55.0	55.0	0.0	(3.0)	-	3.0
ICT & Mobility Solutions	56.0	70.6	(14.6)	(8.0)	4.5	(11.1)
Advanced Medical Solutions	4.0	4.0	0.0	-	(2.0)	2.0
Essential & Green Materials	(10.0)	(58.5)	48.5	8.5	3.5	36.5
Sumitomo Pharma	59.0	35.3	23.7	(4.0)	6.5	21.2
Others	(14.0)	34.2	(48.2)	-	-	(48.2)
Total	150.0	140.5	9.5	(6.5)	12.5	3.5

Analysis of Variance



Consolidated Statement of Cash Flows

17

(Billions of yen)

	FY2025 (Forecast)	FY2024	Variance
Cash flows from operating activities	160.0	233.0	(73.0)
Cash flows from investing activities	(40.0)	85.2	(125.2)
Free cash flows	120.0	318.3	(198.3)
Cash flows from financing activities	(120.0)	(300.8)	180.8
Effect of exchange rate changes on cash and cash equivalents	0.0	(6.8)	6.8
Net change in cash and cash equivalents	0.0	10.7	(10.7)
Interest-bearing debt balance	1,190.0	1,286.1	(96.1)

(Reference)


	FY2023				FY2024				(Billions of yen) FY2025 (Forecast)
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Full year
Agro & Life Solutions	96.8	131.7	118.7	168.4	106.4	118.6	138.1	177.1	530.0
ICT & Mobility Solutions	137.8	152.7	150.7	146.1	152.7	154.8	153.8	145.8	580.0
Advanced Medical Solutions	11.4	13.0	13.8	20.3	13.2	13.6	14.0	21.4	60.0
Essential & Green Materials	219.7	227.6	234.4	204.2	225.0	226.0	222.0	226.1	780.0
Sumitomo Pharma	75.6	76.9	82.3	79.1	90.6	89.8	112.4	105.2	350.0
Others	21.9	21.8	20.1	22.0	24.3	26.5	23.2	25.8	40.0
Total	563.1	623.7	620.0	640.0	612.1	629.3	663.4	701.4	2,340.0

Core Operating Income by Business Segment (Quarterly)

20

	FY2023				FY2024				(Billions of yen) FY2025 (Forecast)
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Full year
Agro & Life Solutions	(7.7)	(1.0)	5.7	29.3	4.9	9.2	5.4	35.5	55.0
ICT & Mobility Solutions	8.3	13.6	22.1	6.1	21.2	22.4	16.1	10.8	56.0
Advanced Medical Solutions	1.6	0.7	0.8	3.1	0.5	(0.1)	0.8	2.8	4.0
Essential & Green Materials	(20.3)	(22.5)	(17.8)	(28.6)	(19.6)	(15.2)	(9.6)	(14.1)	(10.0)
Sumitomo Pharma	(32.2)	(30.8)	(29.1)	(34.5)	0.9	2.1	21.4	10.9	59.0
Others & Adjustments	(3.3)	(3.1)	1.0	(10.6)	(2.2)	5.3	(3.6)	34.6	(14.0)
Total	(53.6)	(43.1)	(17.2)	(35.2)	5.7	23.8	30.6	80.5	150.0

Agro & Life Solutions



Total ¥ 540.2 billion ¥ 24.6 billion from FY2023

Sales price
(7.0)


- Decline in the selling prices for crop protection products in the Americas

Volume
25.4

- Increase in shipments of crop protection products mainly in South America

Foreign exchange
6.2

ICT & Mobility Solutions



Total ¥ 607.0 billion ¥ 19.6 billion from FY2023

Sales price
(3.5)


- Decline in the selling prices of display-related materials

Volume
12.9

- Increase in shipments of display-related materials
- processing materials for semiconductors

Foreign exchange
10.2

Advanced Medical Solutions



Total ¥ 62.1 billion ¥ 3.7 billion from FY2023

Sales price

0.0

Volume

3.5

□ Steady shipments of pharmaceutical chemicals

Foreign exchange

0.2

Essential & Green Materials



Total ¥ 899.0 billion ¥ 13.2 billion from FY2023

Sales price

33.5

□ Increase in the price of naphtha
□ Market conditions for MMA and overseas market prices for synthetic resins improved

Volume


(44.0)

□ Exit from the aluminum business etc.

Foreign exchange

23.7

Sumitomo Pharma




Total ¥ 398.0 billion ¥ 84.2 billion from FY2023

- Sales price**
(5.0) □ NHI drug price revisions in Japan
- Volume**
73.7 □ Higher sales for the three key products
- Foreign exchange**
15.5

Agro & Life Solutions


Total ¥ (55.0) billion ¥ 28.6 billion from FY2023



Price variance	Methionine Profit margins improved due to an increase in market prices and decline in the price of raw materials and fuels
Volume variance etc.	Crop Protection Increase in shipments and reduced effect of increased inventories in the market

ICT & Mobility Solutions


Total ¥ 70.6 billion ¥ 20.5 billion from FY2023



Price variance	Displays	Decline in the selling prices of polarizing films
Cost variance	Displays	Purchase of low-cost raw materials
Volume variance etc.	Displays	Increase in shipments for touchscreen panels
	Semiconductors	Recovery of demand for high-purity chemicals and photoresists

Advanced Medical Solutions

Total ¥ 4.0 billion ¥ (2.1) billion from FY2023




Cost variance

Increase in depreciation and amortization

Essential & Green Materials


Total ¥ (58.5) billion ¥ 30.6 billion from FY2023




Price variance	Profit margins improved due to higher market prices of MMA and petrochemical products
Cost variance	Lower depreciation expenses

Sumitomo Pharma

Total ¥ 35.3 billion ¥ 161.8 billion from FY2023



Sales Revenue



Total ¥530.0 billion ¥ (10.2) billion from FY2024

Sales price

(3.0)

□ Lower market prices for methionine

Volume

(4.3)


□ Decrease in shipments of methionine

□ Increase in overseas shipments of crop protection products

Foreign exchange

(2.9)

Core Operating Income



Total ¥ 55.0 billion ¥ 0.0 billion from FY2024

Price variance

(3.0)

□ Deterioration in trading conditions for methionine

Cost variance


0.0

Volume variance etc.

3.0

□ Increase in overseas shipments of crop protection products

Sales Revenue



Total ¥580.0 billion ¥(27.0) billion from FY2024

Sales price
(8.0)


- Decline in the selling prices of display-related materials

Volume
(22.8)

- Sale of large-size liquid crystal display business
- Increase in shipments of processing materials for semiconductors

Foreign exchange
3.8

Core Operating Income



Total ¥56.0 billion ¥ (14.6) billion from FY2024

Price variance
(8.0)

- Decline in the selling prices of display-related materials

Cost variance
4.5

Volume variance etc.
(11.1)

- Front-loading of the shipment in FY2024 due to such factors as the stronger yen and tariffs
- Increase in shipments of processing materials for semiconductors

Sales Revenue



Total ¥60.0 billion ¥(2.1) billion from FY2024

Sales price

0.0

Volume


(1.8)

□ Decrease in shipments of small molecule drugs

Foreign exchange

(0.3)

Core Operating Income



Total ¥4.0 billion ¥ 0.0 billion from FY2024

Price variance

0.0

Cost variance

(2.0)


□ Increase in depreciation and amortization

Volume variance etc.


2.0

□ Increase in sales of nucleic acid drugs


Sales Revenue



Core Operating Income



Sales Revenue



Total ¥350.0 billion ¥(48.0) billion from FY2024

Sales price
(4.0)

- NHI drug price revisions in Japan


Volume
(34.9)

- Expiration of the patent period for some products

Foreign exchange
(9.1)

- Higher sales for the three key products

Core Operating Income



Total ¥59.0 billion ¥23.7 billion from FY2024

Price variance
(4.0)

- NHI drug price revisions in Japan

Cost variance
6.5

- Rationalization of selling, general, and administrative expenses

Volume variance etc.
21.2

- Higher sales for the three key products

(Billions of yen)

	FY2024	FY2023	Variance	FY2025 (Forecast)
Capital Expenditures	131.7	158.4	(26.7)	158.0
Depreciation and Amortization	131.6	157.5	(25.9)	128.0
Research & Development Expenses	145.2	184.0	(38.8)	156.0
Number of Employees (as of March 31)	29,279	32,161	(2,882)	28,600

(Billions of yen)

	Capital Expenditures		Depreciation & Amortization		R&D Expenses	
	FY2024	FY2023	FY2024	FY2023	FY2024	FY2023
Agro & Life Solutions	20.1	27.8	21.0	22.9	30.6	31.4
ICT & Mobility Solutions	49.2	61.9	34.2	35.5	31.4	30.5
Advanced Medical Solutions	13.0	7.9	7.7	6.5	3.4	3.0
Essential & Green Materials	26.3	29.2	22.8	34.3	9.9	8.0
Sumitomo Pharma	11.5	16.3	24.9	37.1	43.4	84.4
Others	11.6	15.3	21.1	21.2	26.5	26.6
Total	131.7	158.4	131.6	157.5	145.2	184.0


(Billions of yen)

	Capital Expenditures		Depreciation& Amortization		R&D Expenses	
	FY2025 (Forecast)	FY2024	FY2025 (Forecast)	FY2024	FY2025 (Forecast)	FY2024
Agro & Life Solutions	20.5	20.1	20.0	21.0	34.0	30.6
ICT & Mobility Solutions	71.5	49.2	37.0	34.2	33.5	31.4
Advanced Medical Solutions	11.5	13.0	7.5	7.7	4.0	3.4
Essential & Green Materials	32.5	26.3	22.5	22.8	9.5	9.9
Sumitomo Pharma	9.0	11.5	21.5	24.9	44.0	43.4
Others	13.0	11.6	19.5	21.1	31.0	26.5
Total	158.0	131.7	128.0	131.6	156.0	145.2

Company	Sales Revenue		Profit
	FY2024	FY2023	
The Polyolefin Company (Singapore) (Millions of USD)	843	823	↗ Performance result is flat due to an improvement in profit margin and higher sales volume
PCS (Millions of USD)	2,389	2,151	↗ Higher shipments than FY2023, when shut-down maintenance was implemented Profit margins improved
Rabigh Refining and Petrochemical Company (Millions of SAR)	39,349	44,604	↘ Deterioration in petroleum refining margins and trading conditions for petrochemical products
Dongwoo Fine-Chem (Billions of KRW)	20,893	19,585	↗ Increase in sales volume of display-related materials
Sumitomo Chemical Brasil Indústria Química S.A. (Millions of BRL)	4,103	3,922	↗ Improvement in profit margins
Valent North America, and subsidiaries (Millions of USD)	942	935	↘ Deterioration in profit margins


(Billions of yen)

	FY2024	FY2023	Variance	Reasons for Change
Japan	78.5	76.4	2.1	
North America	94.9	93.8	1.1	Foreign currency conversion variance
Central & South America	130.4	134.4	(4.0)	Decline in product selling prices due to intensified competition
Asia (including India)	69.0	59.6	9.4	Increase in shipments due to the resolution of high levels of inventory in the market
Europe & Others	34.7	31.7	3.0	
Total	407.5	395.9	11.6	



Overseas Sales Revenue Ratio

69.9%



Overseas Sales Revenue Ratio

68.0%


Sales Revenue and Profits

Sales Revenue

(¥ billion)


Profit

(¥ billion)




Interest-bearing Liabilities

D/E Ratio



Dividends per share

Net income attributable to owners of the parent



Payout Ratio(%)	30.5	89.9	53.3	24.2	421.2	—	38.2	49.1
-----------------	------	------	------	------	-------	---	------	------

